Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
ALLISON GATLIN

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis agreed late Monday to buy German drugmaker MorphoSys for roughly $2.9 billion, and the biotech stock catapulted to a nearly three-year high.

The deal centers on MorphoSys' cancer treatments, including an experimental drug called pelabresib. Pelabresib is in late-stage testing as a treatment for myelofibrosis. Morphosys is also testing another drug, dubbed tulmimetostat, for solid tumors and lymphomas.

Ahead of the stock market's close, MorphoSys stock rocketed 56%.

Separately, Incyte announced it acquired exclusive rights to a drug it developed with MorphoSys known as tafasitamab. It already sells under the brand names Monjuvi and Minjuvi as a treatment for some lymphomas. Incyte will pay MorphoSys $25 million for the exclusive right to develop and sell tafasitamab worldwide.

In after-hours trading on today's stock market, MorphoSys stock rose another 1.1% to 17.46. The biotech stock has a perfect Relative Strength Rating of 99, meaning shares rank in the top 1% of all stocks, according to IBD Digital.

Novartis stock advanced 1.3% to 104.82. Incyte stock dipped a fraction to 58.03.

Follow Allison Gatlin on X, the platform formerly known as Twitter at @IBD_AGatlin.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.